Skip to main content
Erschienen in: International Journal of Hematology 3/2015

01.09.2015 | Original Article

High frequency of decreased antithrombin level in pregnant women with thrombosis

verfasst von: Yuki Kamimoto, Hideo Wada, Makoto Ikejiri, Kaname Nakatani, Takashi Sugiyama, Kazuhiro Osato, Nao Murabayashi, Norikazu Yamada, Takeshi Matsumoto, Kohshi Ohishi, Hidehiro Ishikawa, Hidekazu Tomimoto, Masaaki Ito, Tomoaki Ikeda

Erschienen in: International Journal of Hematology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Venous thromboembolism (VTE) occurs frequently in pregnant women and is a significant cause of maternal death. Hemostatic abnormalities were examined in 18 pregnant women with thrombosis. We studied five families with congenital antithrombin (AT) deficiency, and two families with congenital protein C (PC) deficiency. One woman with PC deficiency showed protein S (PS) Tokushima. The AT activity levels were significantly lower at the onset of thrombosis in the pregnant women than during the stable state. The PS activity and antigen levels were also significantly lower at the onset of thrombosis. In the patients with congenital AT deficiency, AT activity was significantly low in the stable state and decreased further at the onset of thrombosis. Although AT levels were normal before pregnancy, they subsequently decreased and in two cases the patients required the administration of AT after pregnancy. Gene analysis revealed one family with AT Budapest, one family with AT Toyama, and three families with AT Glasgow. Additionally, there were one family with PC Tochigi and one family with combined heterozygous of PC deficiency and PS Tokushima. In conclusion, the deficiency of natural anticoagulants, especially AT, is an important cause of pregnancy-related VTE.
Literatur
1.
Zurück zum Zitat Franchini M. Haemostasis and pregnancy. Thromb Haemost. 2006;95:401–13.PubMed Franchini M. Haemostasis and pregnancy. Thromb Haemost. 2006;95:401–13.PubMed
2.
3.
Zurück zum Zitat Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006–2010. Obstet Gynecol. 2015;125:5–12.CrossRefPubMed Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006–2010. Obstet Gynecol. 2015;125:5–12.CrossRefPubMed
5.
Zurück zum Zitat Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium—a register-based case-control study. Am J Obstet Gynecol. 2008;198:233–7.CrossRefPubMed Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium—a register-based case-control study. Am J Obstet Gynecol. 2008;198:233–7.CrossRefPubMed
6.
Zurück zum Zitat James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol. 2009;29:326–31.CrossRefPubMed James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol. 2009;29:326–31.CrossRefPubMed
7.
Zurück zum Zitat Conard J, Horellou MH, van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990;63:319–20.PubMed Conard J, Horellou MH, van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990;63:319–20.PubMed
8.
Zurück zum Zitat Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol. 1996;16:742–8.CrossRefPubMed Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol. 1996;16:742–8.CrossRefPubMed
9.
Zurück zum Zitat Friederich PW, Sanson BJ, Simioni P, Zanardi S, Hilsman MV, Girolami A, ten Cate JW, Prins MH. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med. 1996;125:955–60.CrossRefPubMed Friederich PW, Sanson BJ, Simioni P, Zanardi S, Hilsman MV, Girolami A, ten Cate JW, Prins MH. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med. 1996;125:955–60.CrossRefPubMed
10.
Zurück zum Zitat Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342:374–80.CrossRefPubMed Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342:374–80.CrossRefPubMed
11.
Zurück zum Zitat MacCallum P, Bowles L, Keeling D. Diagnosis and management of heritable thrombophilias. BMJ. 2014;17(349):g4387.CrossRef MacCallum P, Bowles L, Keeling D. Diagnosis and management of heritable thrombophilias. BMJ. 2014;17(349):g4387.CrossRef
12.
Zurück zum Zitat Guimicheva B, Czuprynska J, Arya R. The prevention of pregnancy-related venous thromboembolism. Br J Haematol. 2015;168:163–74.CrossRefPubMed Guimicheva B, Czuprynska J, Arya R. The prevention of pregnancy-related venous thromboembolism. Br J Haematol. 2015;168:163–74.CrossRefPubMed
13.
Zurück zum Zitat Nelson-Piercy C, MacCallum P, Mackillop L, on behalf of the Guidelines Committee of the Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. RCOG Green-top Guideline 2009; No. 37a. London: Royal College of Obstetricians and Gynaecologists; 2009. Nelson-Piercy C, MacCallum P, Mackillop L, on behalf of the Guidelines Committee of the Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. RCOG Green-top Guideline 2009; No. 37a. London: Royal College of Obstetricians and Gynaecologists; 2009.
14.
Zurück zum Zitat James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194:1311–5.CrossRefPubMed James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194:1311–5.CrossRefPubMed
15.
Zurück zum Zitat Liu S, Rouleau J, Joseph KS, Sauve R, Liston RM, Young D, Kramer MS. Epidemiology of pregnancy-associated venous thromboembolism: a population-based study in Canada. J Obstet Gynaecol Can. 2009;31:611–20.PubMed Liu S, Rouleau J, Joseph KS, Sauve R, Liston RM, Young D, Kramer MS. Epidemiology of pregnancy-associated venous thromboembolism: a population-based study in Canada. J Obstet Gynaecol Can. 2009;31:611–20.PubMed
16.
Zurück zum Zitat Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.PubMed Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.PubMed
17.
Zurück zum Zitat Ikejiri M, Shindo A, Ii Y, Tomimoto H, Yamada N, Matsumoto T, Abe Y, Nakatani K, Nobori T, Wada H. Frequent association of thrombophilia in cerebral venous sinus thrombosis. Int J Hematol. 2012;95:257–62.CrossRefPubMed Ikejiri M, Shindo A, Ii Y, Tomimoto H, Yamada N, Matsumoto T, Abe Y, Nakatani K, Nobori T, Wada H. Frequent association of thrombophilia in cerebral venous sinus thrombosis. Int J Hematol. 2012;95:257–62.CrossRefPubMed
18.
Zurück zum Zitat Olds RJ, Lane DA, Caso R, Panico M, Morris HR, Sas G, Dawes J, Thein SL. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood. 1992;79:1206–12.PubMed Olds RJ, Lane DA, Caso R, Panico M, Morris HR, Sas G, Dawes J, Thein SL. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood. 1992;79:1206–12.PubMed
19.
Zurück zum Zitat Sakuragawa N, Takahashi K, Kondo S, Koide T. Antithrombin III Toyama: a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis. Thromb Res. 1983;31:305–17.CrossRefPubMed Sakuragawa N, Takahashi K, Kondo S, Koide T. Antithrombin III Toyama: a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis. Thromb Res. 1983;31:305–17.CrossRefPubMed
20.
Zurück zum Zitat Thein SL, Lane DA. Use of synthetic oligonucleotides in the characterization of antithrombin III Northwick Park (393 CGT—TGT) and antithrombin III Glasgow (393 CGT—CAT). Blood. 1988;72:1817–21.PubMed Thein SL, Lane DA. Use of synthetic oligonucleotides in the characterization of antithrombin III Northwick Park (393 CGT—TGT) and antithrombin III Glasgow (393 CGT—CAT). Blood. 1988;72:1817–21.PubMed
21.
Zurück zum Zitat Miyata T, Zheng YZ, Sakata T, Tsushima N, Kato H. Three missense mutations in the protein C heavy chain causing type I and type II protein C deficiency. Thromb Haemost. 1994;71:32–7. Miyata T, Zheng YZ, Sakata T, Tsushima N, Kato H. Three missense mutations in the protein C heavy chain causing type I and type II protein C deficiency. Thromb Haemost. 1994;71:32–7.
22.
Zurück zum Zitat Miyata T, Sakata T, Zheng YZ, Tsukamoto H, Umeyama H, Uchiyama S, Ikusaka M, Yoshioka A, Imanaka Y, Fujimura H, Kambayashi J, Kato H. Genetic characterization of protein C deficiency in Japanese subjects using a rapid and nonradioactive method for single-stand conformational polymorphism analysis and a model building. Thromb Haemost. 1996;76:302–11.PubMed Miyata T, Sakata T, Zheng YZ, Tsukamoto H, Umeyama H, Uchiyama S, Ikusaka M, Yoshioka A, Imanaka Y, Fujimura H, Kambayashi J, Kato H. Genetic characterization of protein C deficiency in Japanese subjects using a rapid and nonradioactive method for single-stand conformational polymorphism analysis and a model building. Thromb Haemost. 1996;76:302–11.PubMed
23.
Zurück zum Zitat Hayashi T, Nishioka J, Shigekiyo T, Saito S, Suzuki K. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood. 1994;83:683–90.PubMed Hayashi T, Nishioka J, Shigekiyo T, Saito S, Suzuki K. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood. 1994;83:683–90.PubMed
24.
Zurück zum Zitat Galambosi PJ, Ulander VM, Kaaja RJ. The incidence and risk factors of recurrent venous thromboembolism during pregnancy. Thromb Res. 2014;134:240–5.CrossRefPubMed Galambosi PJ, Ulander VM, Kaaja RJ. The incidence and risk factors of recurrent venous thromboembolism during pregnancy. Thromb Res. 2014;134:240–5.CrossRefPubMed
25.
Zurück zum Zitat Tanaka H, Katsuragi S, Osato K, Hasegawa J, Nakata M, Murakoshi T, Yoshimatsu J, Sekizawa A, Kanayama N, Ishiwata I, Ikeda T. Increase in maternal death-related venous thromboembolism during pregnancy in Japan (2010–2013). Circ J. 2015;79:1357–62.CrossRefPubMed Tanaka H, Katsuragi S, Osato K, Hasegawa J, Nakata M, Murakoshi T, Yoshimatsu J, Sekizawa A, Kanayama N, Ishiwata I, Ikeda T. Increase in maternal death-related venous thromboembolism during pregnancy in Japan (2010–2013). Circ J. 2015;79:1357–62.CrossRefPubMed
26.
Zurück zum Zitat Shindo A, Wada H, Ishikawa H, Ito A, Asahi M, Ii Y, Ikejiri M, Tomimoto H. Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients. Int J Hematol. 2014;99:437–40.CrossRefPubMed Shindo A, Wada H, Ishikawa H, Ito A, Asahi M, Ii Y, Ikejiri M, Tomimoto H. Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients. Int J Hematol. 2014;99:437–40.CrossRefPubMed
27.
Zurück zum Zitat Terni E, Giannini N, Chiti A, Gialdini G, Orlandi G, Montano V, Orsucci D, Brondi M, Bonuccelli U, Mancuso M. Cerebral sinus venous thrombosis: clinical and pathogenetic perspectives from Tuscany. Blood Coagul Fibrinolysis. 2015 [Epub ahead of print]. Terni E, Giannini N, Chiti A, Gialdini G, Orlandi G, Montano V, Orsucci D, Brondi M, Bonuccelli U, Mancuso M. Cerebral sinus venous thrombosis: clinical and pathogenetic perspectives from Tuscany. Blood Coagul Fibrinolysis. 2015 [Epub ahead of print].
28.
Zurück zum Zitat Hasegawa M, Wada H, Wakabayashi H, Yoshida K, Miyamoto N, Asanuma K, Matsumoto T, Ohishi K, Shimokariya Y, Yamada N, Uchida A, Sudo A. The relationships among hemostatic markers, the withdrawal of fondaparinux due to a reduction in hemoglobin and deep vein thrombosis in Japanese patients undergoing major orthopedic surgery. Clin Chim Acta. 2013;425:109–13.CrossRefPubMed Hasegawa M, Wada H, Wakabayashi H, Yoshida K, Miyamoto N, Asanuma K, Matsumoto T, Ohishi K, Shimokariya Y, Yamada N, Uchida A, Sudo A. The relationships among hemostatic markers, the withdrawal of fondaparinux due to a reduction in hemoglobin and deep vein thrombosis in Japanese patients undergoing major orthopedic surgery. Clin Chim Acta. 2013;425:109–13.CrossRefPubMed
29.
Zurück zum Zitat Jiang Y, McIntosh JJ, Reese JA, Deford CC, Kremer Hovinga JA, Lämmle B, Terrell DR, Vesely SK, Knudtson EJ, George JN. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood. 2014;123:1674–80. Jiang Y, McIntosh JJ, Reese JA, Deford CC, Kremer Hovinga JA, Lämmle B, Terrell DR, Vesely SK, Knudtson EJ, George JN. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood. 2014;123:1674–80.
30.
Zurück zum Zitat Suzuki A, Sanda N, Miyawaki Y, Fujimori Y, Yamada T, Takagi A, Murate T, Saito H, Kojima T. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem. 2010;285:13444–53.PubMedCentralCrossRefPubMed Suzuki A, Sanda N, Miyawaki Y, Fujimori Y, Yamada T, Takagi A, Murate T, Saito H, Kojima T. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem. 2010;285:13444–53.PubMedCentralCrossRefPubMed
31.
Zurück zum Zitat Habe K, Wada H, Ito-Habe N, Suzuki H, Nobori T, Mizutani H. Two patients with antiphospholipid antibody developed disseminated intravascular coagulation. Intern Med. 2013;52:269–72.CrossRefPubMed Habe K, Wada H, Ito-Habe N, Suzuki H, Nobori T, Mizutani H. Two patients with antiphospholipid antibody developed disseminated intravascular coagulation. Intern Med. 2013;52:269–72.CrossRefPubMed
Metadaten
Titel
High frequency of decreased antithrombin level in pregnant women with thrombosis
verfasst von
Yuki Kamimoto
Hideo Wada
Makoto Ikejiri
Kaname Nakatani
Takashi Sugiyama
Kazuhiro Osato
Nao Murabayashi
Norikazu Yamada
Takeshi Matsumoto
Kohshi Ohishi
Hidehiro Ishikawa
Hidekazu Tomimoto
Masaaki Ito
Tomoaki Ikeda
Publikationsdatum
01.09.2015
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1822-0

Weitere Artikel der Ausgabe 3/2015

International Journal of Hematology 3/2015 Zur Ausgabe

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.